dolutegravir/abacavir/lamivudine (Triumeq®)

Reference No. 2365

Publication date:

20/05/2015

Last review date:

27/03/2018

Appraisal information

dolutegravir/abacavir/lamivudine (Triumeq®) 50 mg/600 mg/300 mg film-coated tablet

Company:	ViiV Healthcare UK Ltd
BNF category:	Infections
NMG meeting date:	25/02/2015
AWMSG meeting date:	25/03/2015

Submission Type:	Limited Submission
Status:	Recommended
Advice No:	0415
Ratification by Welsh Government:	15/05/2015

Current Progress

Submission
received

NMG
meeting

AWMSG
meeting

Ratification by
Welsh Government

AWMSG advice

Dolutegravir/abacavir/lamivudine (Triumeq®) is recommended as an option for use within NHS Wales for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. This recommendation applies only in circumstances where the approved Wales Patient Access Scheme is utilised.

Final Appraisal Recommendation (FAR)

Download

dolutegravir_abacavir_lamivudine (Triumeq) 2365 FAR

AWMSG Secretariat Appraisal Report (ASAR)

Download

dolutegravir abacavir lamivudine (Triumeq) 2365 ASAR

Clinical Expert (CE) Summary

Download

dolutegravir abacavir lamivudine (Triumeq) 2365 CE summary